Exploring the potential of circular RNA

Vaccine Insights 2023; 2(1), 5–8

DOI: 10.18609/vac.2023.002

Published: 23 January 2023
Piotr Kowalski

“Circular RNA has the potential to expand the toolbox of therapeutic RNAs and address some of the limitations of current RNA vaccines and therapeutics...”

As the leader of a research group focused on developing novel, clinically relevant delivery technologies for nucleic acid-based therapies, I saw first-hand how the COVID pandemic accelerated manufacturing and scale-up processes and regulatory frameworks for mRNA-based drugs. The pandemic catalyzed academic and industry research and development (R&D) activities in the mRNA field, as well as in the lipid nanoparticle (LNP) technology used to deliver the vaccines. However, there is still huge scope for improvement.